These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33330040)

  • 1. Lung Cancer Immunotherapy in Transplant Patients and in Patients With Autoimmune Diseases.
    Kubiatowski T; Nicoś M; Krawczyk P
    Front Oncol; 2020; 10():568081. PubMed ID: 33330040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease.
    Pantuck M; McDermott D; Drakaki A
    Cancer; 2019 Oct; 125(20):3506-3513. PubMed ID: 31318445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease.
    Spagnoletti A; Platania M; Brambilla M; Occhipinti M; Canziani L; Cabras A; Provenzano L; Leone AG; Ambrosini P; Prelaj A
    Tumori; 2022 Dec; 108(6):609-614. PubMed ID: 34989254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy use outside clinical trial populations: never say never?
    Rzeniewicz K; Larkin J; Menzies AM; Turajlic S
    Ann Oncol; 2021 Jul; 32(7):866-880. PubMed ID: 33771665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Mignard X; Chaabane N; Fallet V; Wislez M
    Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 14. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.
    Nakamura Y
    Front Med (Lausanne); 2019; 6():119. PubMed ID: 31192215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in patients with autoimmune disease.
    Rakshit S; Molina JR
    J Thorac Dis; 2020 Nov; 12(11):7032-7038. PubMed ID: 33282408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.
    Huang Z; Su W; Lu T; Wang Y; Dong Y; Qin Y; Liu D; Sun L; Jiao W
    Front Pharmacol; 2020; 11():578091. PubMed ID: 33117170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.
    Kawashima S; Joachim K; Abdelrahim M; Abudayyeh A; Jhaveri KD; Murakami N
    Korean J Transplant; 2022 Jun; 36(2):82-98. PubMed ID: 35919193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management.
    Wang H; Mustafa A; Liu S; Liu J; Lv D; Yang H; Zou J
    Front Pharmacol; 2019; 10():1254. PubMed ID: 31708780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.